Morpho Detection, Inc. (MDI), a developer of explosives and chemical, biological, radiological, and nuclear (CBRN) detection systems, announced Tuesday that it has entered into an agreement to acquire Tustin, Calif.-based Syagen Technology. Syagen develops products that use mass spectrometry technology, which is an analytical technique used to determine the identity of molecules.
According to a statement, the deal, which has already been approved by the board of directors of both companies, is still subject to Syagen’s shareholder and regulatory approvals.
MDI says the acquisition will strengthen its position in the homeland security market. In addition, the combination of Syagen’s technologies with MDI’s global commercial and service reach is expected to generate strong growth potential.
"Syagen’s unique mass spectrometry technology combined with Morpho Detection’s patented Ion Trap Mobility Spectrometry trace detection will help deliver the solutions customers need for detecting emerging, non-conventional explosives threats," said Dennis Cooke, president and CEO of Morpho Detection. "We are pleased to welcome Syagen’s superb team of mass spectrometry technical experts and their world-class technology and entrepreneurial spirit to the MDI team."